General Information of the Drug (ID: M6APDG01616)
Name
(E)-6-Nitrooctadec-5-enoic Acid
Synonyms
CHEMBL569372; (E)-6-Nitrooctadec-5-enoic Acid
    Click to Show/Hide
Status
Investigative
Structure
3D MOL
Formula
C18H33NO4
InChI
1S/C18H33NO4/c1-2-3-4-5-6-7-8-9-10-11-14-17(19(22)23)15-12-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
InChIKey
ZNCCLONFJQTFGL-BMRADRMJSA-N
PubChem CID
44220889
TTD Drug ID
D0Z4NW
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a therapeutic target for (E)-6-Nitrooctadec-5-enoic Acid. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of (E)-6-Nitrooctadec-5-enoic Acid through regulating the expression of Peroxisome proliferator-activated receptor gamma (PPAR-gamma). [1], [2]
References
Ref 1 The m(6)A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG. Acta Pharmacol Sin. 2022 May;43(5):1311-1323. doi: 10.1038/s41401-021-00756-8. Epub 2021 Aug 30.
Ref 2 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.